The Medical Devices (In Vitro Diagnostic Devices etc.) (Amendment) Regulations 2024
Write the words of this act the way you think they should read. Solon shows your change as a redline against the published text and pins it to that exact text, so it can never be applied to wording you did not see.
Change 1
36 New Part 3A (Performance studies under Regulation (EU) 2017/746)
After Part 3 insert— Part 3A Performance studies under Regulation (EU) 2017/746 Legal representatives and contact persons for performance studies 17B. (1) The first subparagraph of Article 58(4) (requirement to have a legal representative established in the Union) does not apply to a performance study conducted in Northern Ireland if all of the following conditions are met— (a) the performance study is also being conducted in Great Britain; (b) the performance study is not also being conducted in a Member State; (c) the sponsor— (i) is established in Great Britain, or (ii) has a written agreement with a legal representative established in Great Britain who is responsible for ensuring compliance with the sponsor’s obligations under Regulation (EU) 2017/746; (d) the sponsor has a contact person established in Northern Ireland in respect of the performance study. (2) A contact person referred to in this regulation must be the addressee for all communications with the sponsor provided for in Regulation (EU) 2017/746 and any communication with that contact person is deemed to be a communication with the sponsor. (3) The agreement referred to in paragraph (1)(c)(ii) must provide for— (a) the legal representative to be responsible for ensuring compliance with the sponsor’s obligations under Regulation (EU) 2017/746, (b) the legal representative to immediately inform the sponsor of all communications received in its capacity as the sponsor’s legal representative, and (c) the sponsor to share with its legal representative all communications and documentation necessary to enable the legal representative to fulfil its obligations under this regulation. (4) A legal representative referred to in paragraph (1)(c)(ii) must have a written agreement with the contact person to provide for— (a) the contact person to immediately inform the legal representative of all communications received in its capacity as the sponsor’s contact person, and (b) the legal representative to share with the contact person all communications and documentation necessary to enable the contact person to fulfil its obligations under this regulation. (5) Where the sponsor is established in Great Britain, the sponsor must have a written agreement with the contact person to provide for— (a) the contact person to immediately inform the sponsor of all communications received in its capacity as the sponsor’s contact person, and (b) the sponsor to share with the contact person all communications and documentation necessary to enable the contact person to fulfil its obligations under this regulation. (6) Where the sponsor has a legal representative established in Great Britain, the application form drawn up in accordance with Chapter I of Annex XIV and any clinical performance study plan drawn up in accordance with Part A of Annex XIII must include the name, address and contact details of the legal representative established in Great Britain. Ethical review of performance studies 17C. (1) In Regulation (EU) 2017/746 a reference to an ethics committee is a reference to an ethics committee within the meaning of regulation 3(1). (2) In relation to a performance study to which Article 58(5)(b) applies, the sponsor must submit to the Secretary of State a copy of the opinion of the ethics committee as soon as it becomes available and before the performance study starts. Arbitration following the refusal of a performance study application 17D. (1) A sponsor notified of a refusal under Articles 66(3), 67(4) or 74(10) may, within 28 days of being notified, apply to the Institute to appoint an adjudicator to review the refusal. (2) The adjudicator must provide a report to the Secretary of State and the sponsor, setting out any recommendations in respect of the disputed refusal. (3) The Secretary of State must take the report of the adjudicator into account and decide whether to— (a) confirm or alter the grounds for the refusal of the application, (b) authorise the performance study, or (c) in the case of a refusal under Article 66(3), proceed to consider the application under Article 66. (4) The Secretary of State must notify the sponsor of the decision in paragraph (3). (5) The sponsor must pay any fees, costs and expenses of the Institute and its appointed adjudicator that are payable in connection with the application made under paragraph (1). Damage compensation in relation to performance studies 17E. A sponsor of a performance study must hold sufficient insurance (or equivalent financial resources) to meet any potential financial liability in the event of injury or death attributable to participation in the performance study. Retention of documentation relating to performance studies 17F. (1) The liquidator or trustee in bankruptcy of a sponsor of a performance study, or of a sponsor’s legal representative or contact person under Article 58(4), must— (a) retain for the required period any documentation that consists of, or reasonably could consist of, any of the documentation referred to in Annex XIV, and (b) comply with any request made by the Secretary of State during the required period to provide the Secretary of State with the retained documentation. (2) In this regulation, the required period is— (a) in the case of documentation relating to the performance study of a device that was subsequently placed on the market, 10 years after the last device was placed on the market; (b) in any other case, 10 years after the performance study ended. .
36 New Part 3A (Performance studies under Regulation (EU) 2017/746)
After Part 3 insert— Part 3A Performance studies under Regulation (EU) 2017/746 Legal representatives and contact persons for performance studies 17B. (1) The first subparagraph of Article 58(4) (requirement to have a legal representative established in the Union) does not apply to a performance study conducted in Northern Ireland if all of the following conditions are met— (a) the performance study is also being conducted in Great Britain; (b) the performance study is not also being conducted in a Member State; (c) the sponsor— (i) is established in Great Britain, or (ii) has a written agreement with a legal representative established in Great Britain who is responsible for ensuring compliance with the sponsor’s obligations under Regulation (EU) 2017/746; (d) the sponsor has a contact person established in Northern Ireland in respect of the performance study. (2) A contact person referred to in this regulation must be the addressee for all communications with the sponsor provided for in Regulation (EU) 2017/746 and any communication with that contact person is deemed to be a communication with the sponsor. (3) The agreement referred to in paragraph (1)(c)(ii) must provide for— (a) the legal representative to be responsible for ensuring compliance with the sponsor’s obligations under Regulation (EU) 2017/746, (b) the legal representative to immediately inform the sponsor of all communications received in its capacity as the sponsor’s legal representative, and (c) the sponsor to share with its legal representative all communications and documentation necessary to enable the legal representative to fulfil its obligations under this regulation. (4) A legal representative referred to in paragraph (1)(c)(ii) must have a written agreement with the contact person to provide for— (a) the contact person to immediately inform the legal representative of all communications received in its capacity as the sponsor’s contact person, and (b) the legal representative to share with the contact person all communications and documentation necessary to enable the contact person to fulfil its obligations under this regulation. (5) Where the sponsor is established in Great Britain, the sponsor must have a written agreement with the contact person to provide for— (a) the contact person to immediately inform the sponsor of all communications received in its capacity as the sponsor’s contact person, and (b) the sponsor to share with the contact person all communications and documentation necessary to enable the contact person to fulfil its obligations under this regulation. (6) Where the sponsor has a legal representative established in Great Britain, the application form drawn up in accordance with Chapter I of Annex XIV and any clinical performance study plan drawn up in accordance with Part A of Annex XIII must include the name, address and contact details of the legal representative established in Great Britain. Ethical review of performance studies 17C. (1) In Regulation (EU) 2017/746 a reference to an ethics committee is a reference to an ethics committee within the meaning of regulation 3(1). (2) In relation to a performance study to which Article 58(5)(b) applies, the sponsor must submit to the Secretary of State a copy of the opinion of the ethics committee as soon as it becomes available and before the performance study starts. Arbitration following the refusal of a performance study application 17D. (1) A sponsor notified of a refusal under Articles 66(3), 67(4) or 74(10) may, within 28 days of being notified, apply to the Institute to appoint an adjudicator to review the refusal. (2) The adjudicator must provide a report to the Secretary of State and the sponsor, setting out any recommendations in respect of the disputed refusal. (3) The Secretary of State must take the report of the adjudicator into account and decide whether to— (a) confirm or alter the grounds for the refusal of the application, (b) authorise the performance study, or (c) in the case of a refusal under Article 66(3), proceed to consider the application under Article 66. (4) The Secretary of State must notify the sponsor of the decision in paragraph (3). (5) The sponsor must pay any fees, costs and expenses of the Institute and its appointed adjudicator that are payable in connection with the application made under paragraph (1). Damage compensation in relation to performance studies 17E. A sponsor of a performance study must hold sufficient insurance (or equivalent financial resources) to meet any potential financial liability in the event of injury or death attributable to participation in the performance study. Retention of documentation relating to performance studies 17F. (1) The liquidator or trustee in bankruptcy of a sponsor of a performance study, or of a sponsor’s legal representative or contact person under Article 58(4), must— (a) retain for the required period any documentation that consists of, or reasonably could consist of, any of the documentation referred to in Annex XIV, and (b) comply with any request made by the Secretary of State during the required period to provide the Secretary of State with the retained documentation. (2) In this regulation, the required period is— (a) in the case of documentation relating to the performance study of a device that was subsequently placed on the market, 10 years after the last device was placed on the market; (b) in any other case, 10 years after the performance study ended. .
One line that says what changes, such as "Halve the dog tax".
Who it helps, what it costs, what it fixes. It is what persuades people to support it.
How this law is officially changed
Solon does not know this law's official route yet. The proposal is recorded all the same, and the route appears here once its source is added.
A proposal here is not law. Support on Solon is evidence that people want the change; the official route says what it takes to make it law.
Sign in to file your proposal. What you have written stays on this page.
Sign in to file itThink it through
Ask what your change would do, who would gain and who would bear a cost, and where something like it is already law. The assistant reads your draft as it stands, cites the law and the studies it finds, and takes no side. What you file stays yours.